Quince Therapeutics is on track for a pivotal readout from its Phase 3 NEAT trial in Ataxia-Telangiectasia (A-T) expected in mid-Q1 2026. The trial, redesigned to correct prior protocol issues, is 90% powered to detect statistically significant improvements in neurologic function among children aged 6–9 over a 24-week dosing period. Regulatory authorities have provided written guidance on primary and secondary endpoints, and the company’s erythrocyte-based delivery platform (AIDE) is designed to deliver chronic low-dose corticosteroids with a reduced systemic toxicity profile. If successful, eDSP could address an orphan disease market estimated at over $1 billion annually with no current approved therapies.

Seven analysts cover Quince Therapeutics, assigning a consensus rating of Moderate Buy. Coverage includes one Sell, one Hold, four Buy and one Strong Buy recommendation. The average 12-month price objective stands at $8.00, up from previous consensus levels. Recent research notes include a revised Buy rating from D. Boral Capital raising its target from $4.00 to $5.00, a reaffirmation of Market Outperform from Citigroup, and a Sell (e+) stance from Weiss Ratings. Analyst models project that the lead asset could drive positive cash flow by late 2027, contingent on trial success and commercial launch dynamics in orphan neurology markets.

Institutional ownership in QNCX has risen to 30.75%, with several hedge funds initiating or expanding stakes during the past two quarters. XTX Topco Ltd initiated a position valued at $37,000, Rockefeller Capital Management added a new stake worth $280,000, GSA Capital Partners grew its holding by 158% to 87,235 shares, and Union Square Park Capital Management boosted its position by 86% to 224,746 shares. These moves reflect growing confidence in the eDSP platform’s potential and the upcoming data catalyst from the NEAT trial.